Metabiomed Co Ltd
Metabiomed Co Ltd is a South Korean company engaged in the development, production, and distribution of medical equipment and supplies, primarily serving the healthcare services and equipment sector.
Business. Metabiomed Co Ltd (059210.KQ) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in South Korea, the company is primarily listed on the KOSDAQ exchange.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Metabiomed Co Ltd (059210.KQ) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in South Korea, the company is primarily listed on the KOSDAQ exchange.
Metabiomed maintains a capital structure with a debt-to-equity ratio of 0.86, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.4, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow is negative at -646.62 million KRW, which may signal reinvestment in operations or capital expenditures.
In terms of profitability, Metabiomed's return on equity (ROE) is 7.55%, and return on assets (ROA) is 3.49%, both of which are below the typical thresholds for high-performing firms in the medical equipment industry. The company's operating margin is 21.43% (calculated from operating income of 4.82 billion KRW on revenue of 22.5 billion KRW), which is a strong indicator of operational efficiency.
Geographically and segment-wise, Metabiomed's revenue concentration is not disclosed in the available data, but the company's operations are primarily based in South Korea. The lack of detailed segment reporting limits the ability to assess geographic or product diversification.
The company's growth trajectory is not explicitly outlined in the data, but the recent actual revenue of 102.95 billion KRW and EPS of 438.00 KRW suggest a stable performance in the most recent reporting period. However, without forward-looking guidance or historical growth rates, it is difficult to determine the pace of future expansion.
Risk factors include a medium liquidity risk, as the company's net cash position is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. The company's capital expenditures of -7.04 billion KRW indicate a significant investment in long-term assets, which could impact short-term liquidity.
Recent events include the latest actual EPS and revenue figures, which align with the company's reported financial performance. No recent filings or transcripts are available to provide additional context on strategic initiatives or operational changes.
- Metabiomed has a moderate debt load with a debt-to-equity ratio of 0.86.
- The company's ROE of 7.55% and ROA of 3.49% suggest room for improvement in asset utilization and profitability.
- Free cash flow is negative, indicating reinvestment or capital expenditure activity.
- The company's liquidity position is medium, with a current ratio of 1.4.
- No significant dilution risk is currently present.
- Recent actual revenue and EPS figures indicate stable performance in the latest reporting period.
Bull / Bear case
Generated · model-assistedNet income surged 122.3% year-over-year to KRW 22.4 billion, demonstrating strong recent profitability acceleration.
Revenue grew 13.2% year-over-year to KRW 94.0 billion, showing consistent top-line expansion.
High credit risk flag suggests significant potential for financial distress or default issues.
Debt-to-equity ratio of 0.86 is in the bottom quartile, indicating excessive leverage compared to peers.
Free cash flow turned negative to KRW -5.0 billion in FY0, reversing previous positive trends.
Medium liquidity risk flag indicates potential difficulties in meeting short-term financial obligations.
Revenue CAGR of -2.2% over four years suggests long-term top-line stagnation despite recent growth.
In focus — financials by report
Revenue KRW 102.95B, +9,5% YoY; Operating income +24,0% YoY.
- ▍Revenue KRW 102.95B, +9,5% YoY
- ▍Operating income +24,0% YoY
- ▍Net income −51,0% YoY
- ▍Free cash flow −132,0% YoY
- ▍Net margin 10.7%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Metabiomed Co Ltd Market data — financials · 2026-05-26
- Metabiomed Co Ltd Market data — analyst estimates · 2026-05-26